Media coverage about Anika Therapeutics (NASDAQ:ANIK) has been trending somewhat positive on Thursday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.185704966485 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Anika Therapeutics (ANIK) Announces HA-Based Bone Void Filer Receives FDA 510(k) Clearance (streetinsider.com)
- Hovnanian and Kindred climb while Callaway Golf slumps (marketbeat.com)
- Anika Therapeutics Inc. (ANIK) Given Average Recommendation of “Strong Buy” by Analysts (americanbankingnews.com)
- BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment (reuters.com)
- BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment (ANIK) (markets.businessinsider.com)
A number of equities research analysts have issued reports on ANIK shares. Barrington Research increased their target price on shares of Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. BidaskClub lowered shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 14th.
Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.05. The company had revenue of $27.18 million for the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.59 EPS. research analysts expect that Anika Therapeutics will post 1.9 EPS for the current year.
In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Charles H. Sherwood sold 22,228 shares of the stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $60.06, for a total transaction of $1,335,013.68. Following the completion of the sale, the chief executive officer now directly owns 158,297 shares in the company, valued at $9,507,317.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,886 shares of company stock worth $2,606,455. 6.57% of the stock is owned by company insiders.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
What are top analysts saying about Anika Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics and related companies.